Perjeta (pertuzumab) / Roche 
Welcome,         Profile    Billing    Logout  
 80 Diseases   201 Trials   201 Trials   5515 News 


«12...1617181920212223242526...6970»
  • ||||||||||  QL1209 (pertuzumab biosimilar) / Qilu Pharma, Perjeta (pertuzumab) / Roche
    Clinical, Journal:  A randomized, double-blind, parallel control study to evaluate the biosimilarity of QL1209 with Perjeta in healthy male subjects. (Pubmed Central) -  Sep 13, 2022   
    The incidence of drug-related adverse events was 95.6% and 95.5% in the QL1209 and Perjeta groups, respectively, also comparable between the two groups. The results of this comparative clinical pharmacology study demonstrated the PK similarity of QL1209 (420 mg: 14 ml) and Perjeta (420 mg: 14 ml) and there was no significant difference in safety and immunogenicity between QL1209 and Perjeta manufactured by Roche Pharma AG.
  • ||||||||||  Review, Journal:  Radiation therapy and targeted therapies: Risks and opportunities (Pubmed Central) -  Sep 7, 2022   
    Recruiting --> Active, not recruiting This review provides a point of view in the current state of knowledge, and its limitations highlight the need for more solid data in a field full of promise.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Journal:  Does neoadjuvant chemotherapy regimen affect sarcopenia status in patients with breast cancer? (Pubmed Central) -  Sep 7, 2022   
    Patients receiving TCHP have a higher risk of muscle mass loss than those receiving AC-T. Considering the severe SMI decline observed in the TCHP group, further prospective studies are called for to examine treatment-induced sarcopenia and its relationship to body composition.
  • ||||||||||  Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    A Unique Case of HER2 Positive Adenocarcinoma of the Small Bowel (Crown Ballroom) -  Sep 4, 2022 - Abstract #ACG2022ACG_3331;    
    In this case, we report an ongoing complete response to Her2-directed therapy in a patient with an ERBB2 mutation. HER2 positive adenocarcinoma of the small bowel is uncommon, and using next generation sequencing should be considered in all patients with metastatic disease to allow for targeted therapy.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Journal:  Adhesion strength and anti-tumor agents regulate vinculin of breast cancer cells. (Pubmed Central) -  Sep 3, 2022   
    Additionally, treated cells required greater adhesion forces to detach from the ECM, thus preventing detachment events of cancer cells from the ECM, and therefore, the probability of cell motility, migration, and metastasis was confined. Furthermore, post-detachment and post-treatment vinculin levels were increased, indicating tighter cell-ECM junctions, hence limiting the probability of cell detachment and, therefore, cell motility and migration.
  • ||||||||||  Kadcyla (ado-trastuzumab emtansine) / Roche, Avastin (bevacizumab) / Roche, Perjeta (pertuzumab) / Roche
    Clinical Characteristics and Pathways of Care of Breast Cancer Patients Receiving Targeted Therapy in Hungary (In-person; Virtual) -  Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_2578;    
    Patients were treated with different targeted therapies, i.e., bevacizumab (n=49), trastuzumab (n=216), trastuzumab emtansine (n=7), pertuzumab (n=16) and lapatinib (n=13). The availability and analysis of real-world data contribute to optimizing the management, and consequently, health outcomes of future breast cancer patients.
  • ||||||||||  Kadcyla (ado-trastuzumab emtansine) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Trial completion date, Trial primary completion date:  Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer (clinicaltrials.gov) -  Sep 1, 2022   
    P2,  N=20, Not yet recruiting, 
    Future studies could target patients with additional risks of recurrence or metastases. Trial completion date: Jun 2024 --> Jun 2026 | Trial primary completion date: Jun 2022 --> Jun 2025
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy:  To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH) (clinicaltrials.gov) -  Sep 1, 2022   
    P2,  N=144, Active, not recruiting, 
    Trial completion date: Jun 2024 --> Jun 2026 | Trial primary completion date: Jun 2022 --> Jun 2025 Recruiting --> Active, not recruiting | Trial completion date: Aug 2022 --> Nov 2022 | Trial primary completion date: Apr 2022 --> Nov 2022
  • ||||||||||  Irene (pyrotinib) / Jiangsu Hengrui Medicine, Aidixi (disitamab vedotin) / Rongchang Pharma, Seagen
    Journal:  Long-term remission under Disitamab Vedotin (RC48) in HR-positive/HER2-positive metastatic breast cancer with brain meningeal, and bone marrow involvement: A case report. (Pubmed Central) -  Aug 31, 2022   
    The patient initially responded well to 26 cycles of the first-line anti-HER2 targeted therapy plus chemotherapy (trastuzumab+pertuzumab+nab-paclitaxel) combined with whole-brain radiotherapy...Subsequently, 4 cycles of second-line treatment (trastuzumab + pyrotinib + capecitabin) were continued until the levels of blood tumor markers CEA, CA15-3 and CA125 were elevated, and systemic PD was able to be attained (the brain metastases were rated as stable disease)...The overall survival was >3 years. The present study showcased that RC48 was effective and tolerable for a patient with HR- and HER2-positive BMBC.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Journal:  Cardiac safety analysis of anti-HER2-targeted therapy in early breast cancer. (Pubmed Central) -  Aug 30, 2022   
    However, subgroup analysis suggests that in the presence of coronary artery disease (CAD) and sequential treatment with anthracene, trastuzumab and pertuzumab may increase the cardiac burden compared with trastuzumab. Hs-TnI and QTc may be useful in monitoring and predicting cardiotoxicity associated with anti-HER2 targeted therapy for early breast cancer.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Trial completion date, Trial primary completion date:  Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab (clinicaltrials.gov) -  Aug 29, 2022   
    P2,  N=174, Recruiting, 
    Hs-TnI and QTc may be useful in monitoring and predicting cardiotoxicity associated with anti-HER2 targeted therapy for early breast cancer. Trial completion date: Jul 2023 --> Jul 2025 | Trial primary completion date: Jul 2022 --> Jul 2024
  • ||||||||||  SIBP-01 (trastuzumab biosimilar) / Sinopharm
    Review, Journal:  Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer. (Pubmed Central) -  Aug 27, 2022   
    This systematic review describes and analyzes the so-far published studies concerning the use of the available trastuzumab biosimilars in HER-positive early and metastatic breast cancer in terms of efficacy, safety, and cost-benefit ratio. An attempt was also made to draw some conclusions and to comment on future needs and perspectives.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Journal:  Chemotherapy-associated oral microbiome changes in breast cancer patients. (Pubmed Central) -  Aug 27, 2022   
    In conclusion, the role of microbiota in the oral side effects of chemotherapeutic treatment needs to be considered and should be analyzed in more detail using larger patient cohorts. Oral side effects in breast cancer patients undergoing chemotherapy are a common burden and should be treated for a better tolerability of the therapy.
  • ||||||||||  Perjeta (pertuzumab) / Roche
    Enrollment open, Trial completion date, Trial primary completion date:  HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (clinicaltrials.gov) -  Aug 25, 2022   
    P1,  N=32, Recruiting, 
    The effectiveness and safety data are consistent with those reported in clinical trials of pertuzumab in patients with HER2+ breast cancer, with no new safety concerns. Active, not recruiting --> Recruiting | Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Aug 2022 --> Aug 2023
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Clinical data, Journal:  Impact of age on clinical outcomes and efficacy of adjuvant dual anti-HER2 targeted therapy. (Pubmed Central) -  Aug 12, 2022   
    P3
    These findings support minimal axillary surgical staging for HER2-positive breast cancer patients who experience pCR or RCB I in trials of investigational HER2-targeted regimens. In patients with HER2-positive early BC treated with modern anticancer therapies, young age did not demonstrate either prognostic or predictive value, irrespective of hormone receptor status.
  • ||||||||||  Journal:  Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update. (Pubmed Central) -  Aug 11, 2022   
    HER2-targeted therapy can continue until time of progression or unacceptable toxicities. For patients with HER2-positive and estrogen receptor-positive or progesterone receptor-positive breast cancer, clinicians may recommend either standard first-line therapy or, for selected patients, endocrine therapy plus HER2-targeted therapy or endocrine therapy alone.Additional information is available at www.asco.org/breast-cancer-guidelines.
  • ||||||||||  Perjeta (pertuzumab) / Roche
    Chemoenzymatic approach to the synthesis of site-specifically modified radioimmunoconjugates (W176a (McCormick Place Convention Center)) -  Aug 9, 2022 - Abstract #ACSFall2022ACS_Fall_10519;    
    In addition, I will discuss how our study of this approach has led to a better understanding of the interplay between radioimmunoconjugates and the immune system, particularly Fcγ receptors. Finally, I will share the latest results from our ongoing first-in-human clinical trial in which 89Zr-labeled pertuzumab synthesized via our chemoenzymatic bioconjugation strategy has been deployed for the immunoPET imaging of patients with HER2-positive breast and gastric cancers.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Enrollment open, Trial initiation date, IO biomarker:  A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer (clinicaltrials.gov) -  Aug 5, 2022   
    P2,  N=100, Recruiting, 
    ClinicalTrials.gov identifier: NCT01796197 (https://clinicaltrials.gov/ct2/show/NCT01796197); registered on February 21, 2013. Not yet recruiting --> Recruiting | Initiation date: Jul 2022 --> Oct 2021
  • ||||||||||  Trodelvy (sacituzumab govitecan-hziy) / Everest Medicines, Gilead, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Journal:  Relationship between the expression of complement inhibitory proteins and therapeutic efficacy of antibodies in breast cancer. (Pubmed Central) -  Aug 4, 2022   
    This review describes the structure of mCRPs and analyzes their expression using transcriptomic databases from breast cancer patients, in addition to collecting information on mCRPs interactions and signaling in tumor cells. Given that mCRPs are relevant targets, several strategies that have been explored for their inhibition and regulation in order to increase therapeutic efficacy and prevent cancer resistance and progression are described.
  • ||||||||||  Kadcyla (ado-trastuzumab emtansine) / Roche, Keytruda (pembrolizumab) / Merck (MSD), Perjeta (pertuzumab) / Roche
    EDU 03 - (INTERACTIVE) When Should I Hold Radiation? – Delivery of Radiation with Novel Systemic Agents for Breast Cancer (Henry B. Gonzalez Convention Center, Room 217) -  Aug 1, 2022 - Abstract #ASTRO2022ASTRO_277;    
    This session is devoted to these highly relevant clinical questions which commonly arise in breast cancer patients treated with modern radiotherapy and systemic treatments. To participate in Q&A or polls go to www.astro.org/AMSocialQA.Explain potential biological mechanisms by which systemic and targeted therapies impact radiotherapy in breast cancer patients.Identify systemic and targeted therapies that are radiosensitizing or radioinhibitory agents in breast cancer patients.Discuss optimal timing of radiotherapy in breast cancer patients treated with systemic therapy and ongoing clinical trials and potential novel combinations.
  • ||||||||||  Review, Journal:  Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer. (Pubmed Central) -  Jul 29, 2022   
    New agents, such as trastuzumab-deruxtecan or tucatinib in combination with capecitabine and trastuzumab, have also shown a significant improvement in the metastatic setting...In addition, HER2+ BC is known to be more immunogenic than other BC subgroups, with high variability between tumors. Different immunotherapeutic agents such as HER-2 therapy plus checkpoint inhibitors, or new vaccines approaches have been investigated in this setting, with promising but controversial results obtained to date.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Preclinical, Journal:  Therapeutic Response Monitoring with Zr-DFO-Pertuzumab in HER2-Positive and Trastuzumab-Resistant Breast Cancer Models. (Pubmed Central) -  Jul 29, 2022   
    Additionally, HER2 downregulation evaluated by immuno-PET imaging was verified by western blot analysis and immunofluorescence staining which resulted in a significant reduction in the tumor's HER2 level in 17-DMAG-treated JIMT-1 tumors. Zr-DFO-pertuzumab immuno-PET may be clinically translated to select pertinent patients for HER2-targeted therapy and to monitor the therapeutic response in HER2-positive cancer patients under various HER2-targeted therapeutics treatments.